On 29 April 2025, Arovella CEO and MD, Dr Michael Baker, presented an investor webinar to provide an update following the release of the Company’s Appendix 4C quarterly while outlining next steps for Arovella throughout the rest of 2025 as it moves toward Phase 1 in-human trials.
Investor Webinar recording
Previous
Previous
ALA exclusive iNKT technology option with Baylor
Next
Next